Advertisement

Topics

Clinical Trials About "A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes" RSS

14:12 EDT 23rd October 2018 | BioPortfolio

We list hundreds of Clinical Trials about "A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes" on BioPortfolio

We have published hundreds of A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes news stories on BioPortfolio along with dozens of A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes Clinical Trials and PubMed Articles about A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes Companies in our database. You can also find out about relevant A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes Drugs and Medications on this site too.

Showing "Trial Investigating Effect NN1250 Japanese Subjects With Type" Clinical Trials 1–25 of 44,000+

Extremely Relevant

A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes

This trial is conducted in Japan. The aim of this clinical trial is to investigate the effect of NN1250 in Japanese subjects with type 1 diabetes.


A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes

This trial is conducted in Europe. The aim of this clinical trial is to evaluate the variability in the blood glucose-lowering effect of NN1250 in subjects with type 1 diabetes.

A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes

This trial is conducted in Europe. The aim of this clinical trial is to investigate the blood glucose lowering effect of NN1250 in young and elderly subjects with type 1 diabetes.


A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes

This trial is conducted in Europe. The aim of this clinical trial is to evaluate the effect on the blood glucose-lowering effect of NN1250 in subjects with type 1 diabetes.

A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function

This trial is conducted in Europe. The aim of this clinical trial is to evaluate if the NN1250 concentration-time curve is altered to such an extent that the dose should be adjusted in subjects with impaired renal function compared to the dose for subjects with normal renal function.

Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes

This trial is conducted in Europe. The aim of the trial is to investigate the pharmacodynamic properties (effect) by comparing two NN1250 formulations in subjects with type 1 diabetes.

A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes

This trial is conducted in Europe. The aim of this clinical trial is to look into the concentration of NN1250 in the blood after one injection of NN1250 in children, adolescents and adults with Type 1 diabetes

The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin

This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the pharmacodynamic (effect) and pharmacokinetic (exposure of drug) properties of NN1250 in subjects with type 2 diabetes of different race and/or ethnicity.

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes

This trial is conducted in Europe and in the United States of America (USA). The aim of the trial is to investigate the efficacy and safety of NN1250 in subjects with type 1 diabetes.

Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics

This trial is conducted in Europe. The aim of this clinical trial is to compare the blood glucose lowering effect of NN5401 with NN1250 and insulin aspart in subjects with type 1 diabetes.Where the trial participant will receive one single dose of each trial product in varying order.

A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function

This trial is conducted in Europe. The aim of this clinical trial is to evaluate if the pharmacokinetic and safety profiles of NN1250 are altered to such an extent that the dose should be adjusted in subjects with impaired liver function compared to the dose for subjects with normal liver function.

Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

This trial will be conducted in Africa, Asia, North America and South America. The aim of this clinical trial is to compare NN1250 with sitagliptin, as add-on to subject's own current oral antidiabetic (OAD) treatment, in subjects with type 2 diabetes inadequately controlled with 1-2 OADs (metformin, sulphonylurea, glinides or pioglitazone).

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of the trial is to compare two NN1250 formulations with each other and with insulin glargine, all in combination with insulin aspart in subjects with type 1 diabetes

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

This trial is conducted in Europe and North America. The aim of this clinical trial is to compare NN1250 with insulin glargine, as add-on to subject's ongoing treatment with metformin and/or DPP-4 inhibitors, in patients with type 2 diabetes being treated with oral anti-diabetic drugs (OADs).

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

This trial is conducted in South Africa, Europe and North America. The aim of this trial is to compare efficacy and safety of NN1250 with insulin glargine, as add-on to subject's ongoing treatment with metformin and/or DPP-4 inhibitors, in patients with type 2 diabetes being treated with oral anti-diabetic drugs (OADs) qualifying for intensified treatment.

Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics

This trial is conducted in Europe. The aim of this clinical trial is to evaluate the hypoglycaemic response (the response to low blood sugar) to NN1250 in subjects with type 1 diabetes. The trial is designed as a two-period, crossover trial where the trial participant is randomised to one of two treatment periods.

A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics

This trial is conducted in Europe.The aim is to compare changes in blood sugar and the number of periods where carbohydrate supplementation is needed to treat low blood sugar, during two different treatments with NN1250 in type 1 diabetics

A Trial Investigating the Possible Difference in Development of Type 2 Diabetes Between Caucasian and Japanese Subjects

This trial is conducted in Europe and Japan. The aim of this clinical trial is to investigate the possible difference in the development of type 2 diabetes in a Japanese and a Caucasian population. Healthy subjects, subjects with impaired glucose tolerance, as well as subjects with type 2 diabetes will be included in the trial. The development of type 2 diabetes across the cohort will be investigated with regard to insulin sensitivity and B-cell capacity.

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

This trial will be conducted in Europe and the United States of America (USA). The aim of this clinical trial is to compare NN1250 with insulin glargine in subjects with type 2 diabetes never treated with insulin. All oral anti-diabetic drug (OAD) treatment will be discontinued when trial participant enters the trial with the exception of metformin and DPP-IV inhibitor treatment (only in countries where DPPIV inhibitor treatment is approved for combination treatment together ...

Comparison of Two NN1250 Formulations in Healthy Volunteers

This trial is conducted in North America. The aim of this clinical trial is to investigate if two formulations of NN1250 have the same level of drug exposure to the body.

Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

This trial is conducted in Asia, Europe, Japan and South America. The aim of the trial is to compare NN1250 with insulin detemir, both combined with insulin aspart, in patients with type 1 diabetes.

Relevant

A Bridging Trial Comparing Org 25969 at Reappearance of T2 in Japanese and Caucasian Subjects. Part A: Japanese Subjects (19.4.208A)(P05956)(COMPLETED)

The objective of the trial was to establish the dose-response of T2 in Japanese and Caucasian Subjects. Part A: Japanese Subjects

Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes

This trial is conducted in Africa, Europe and the United States of America (USA). The aim of the trial is to compare NN1250 plus insulin aspart with insulin glargine plus insulin aspart in patients with type 1 diabetes.

Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes

This trial is conducted in Japan. The aim of this research trial is to evaluate the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in Japanese subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to...

Effect of NN5401 in Japanese Subjects With Type 1 Diabetes

This trial is conducted in Japan. The aim of this clinical trial is to investigate the blood sugar lowering effect of NN5401 in Japanese subjects with type 1 diabetes. Each subject will be randomised to one of the two possible treatment sequences (NN5401 followed by biphasic insulin aspart 30 or biphasic insulin aspart 30 followed by NN5401).


More From BioPortfolio on "A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes"

Advertisement
Quick Search
Advertisement
Advertisement